UBS Group Initiates Coverage on Avantor (NYSE:AVTR)

UBS Group began coverage on shares of Avantor (NYSE:AVTR) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The firm set a “neutral” rating and a $16.00 price target on the stock. UBS Group’s price target would suggest a potential upside of 4.71% from the company’s current price.

A number of other equities research analysts also recently issued reports on the stock. Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Barclays lifted their price objective on shares of Avantor from $7.00 to $8.00 and gave the stock an “underweight” rating in a research note on Wednesday, June 24th. Sanford C. Bernstein initiated coverage on shares of Avantor in a research report on Friday, June 26th. They set a “market perform” rating and a $10.50 target price on the stock. Stifel Nicolaus increased their price target on shares of Avantor from $8.00 to $15.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Finally, Morgan Stanley increased their price target on shares of Avantor from $10.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.47.

Avantor Price Performance

Shares of Avantor stock opened at $15.28 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. Avantor has a 12 month low of $7.26 and a 12 month high of $15.93. The stock has a 50 day moving average of $12.82 and a 200 day moving average of $10.02. The firm has a market cap of $10.34 billion, a PE ratio of -18.19, a PEG ratio of 11.30 and a beta of 0.89.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the prior year, the company earned $0.24 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts expect that Avantor will post 0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AVTR. Royal Bank of Canada boosted its holdings in Avantor by 104.3% during the 1st quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock valued at $3,302,000 after acquiring an additional 104,022 shares during the period. Empowered Funds LLC increased its stake in Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after purchasing an additional 5,075 shares during the period. Cetera Investment Advisers lifted its position in shares of Avantor by 40.2% during the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock worth $542,000 after purchasing an additional 11,543 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Avantor during the second quarter worth $232,000. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Avantor by 214.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.